Efficacy and safety of icotrokinra (JNJ2113) for moderate-to-severe plaque psoriasis: a systematic review and metaanalysis of randomized controlled trials
Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs and offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time.